← Back to Screener
Minerva Neurosciences, Inc (NERV)
Price$6.89
Favorite Metrics
Price vs S&P 500 (26W)177.64%
Price vs S&P 500 (4W)-20.24%
Market Capitalization$289.51M
P/E Ratio (Annual)201.05x
All Metrics
Book Value / Share (Quarterly)$1.51
P/TBV (Annual)4.33x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.31
Price vs S&P 500 (YTD)63.27%
EPS (TTM)$-26.74
10-Day Avg Trading Volume0.24M
EPS Excl Extra (TTM)$-26.74
EPS (Annual)$0.19
ROI (Annual)-623.87%
Net Profit Margin (5Y Avg)-491.62%
Cash / Share (Quarterly)$1.90
P/E Normalized (Annual)201.05x
ROA (Last FY)3.88%
EBITD / Share (TTM)$-34.77
ROE (5Y Avg)-191.87%
Cash Flow / Share (Annual)$-0.31
P/B Ratio36.19x
P/B Ratio (Quarterly)4.28x
Net Income / Employee (Annual)$0
Net Interest Coverage (TTM)-2584.50x
ROA (TTM)-620.09%
EV / EBITDA (TTM)25.64x
EPS Incl Extra (Annual)$0.19
Current Ratio (Annual)36.28x
Quick Ratio (Quarterly)35.98x
3-Month Avg Trading Volume0.18M
52-Week Price Return342.47%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.49
P/S Ratio (Annual)7.03x
Asset Turnover (Annual)0.71x
52-Week High$12.46
Operating Margin (5Y Avg)-476.85%
EPS Excl Extra (Annual)$0.19
Tangible BV CAGR (5Y)-35.67%
26-Week Price Return186.38%
Quick Ratio (Annual)35.98x
13-Week Price Return56.15%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)36.28x
Enterprise Value$267.204
Book Value / Share Growth (5Y)-42.53%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)4.71%
Cash / Share (Annual)$1.90
3-Month Return Std Dev113.42%
Net Income / Employee (TTM)$-42
ROE (Last FY)-623.87%
Net Interest Coverage (Annual)-432.67x
EPS Basic Excl Extra (Annual)$0.19
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-26.74
ROI (TTM)-169.62%
Pretax Margin (5Y Avg)-501.48%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.49
Price vs S&P 500 (52W)307.38%
Year-to-Date Return67.41%
5-Day Price Return18.07%
EPS Normalized (Annual)$0.19
ROA (5Y Avg)-33.70%
Net Profit Margin (Annual)4.71%
Month-to-Date Return11.70%
Cash Flow / Share (TTM)$-3.53
EBITD / Share (Annual)$0.19
Operating Margin (Annual)4.49%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-191.73%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-26.74
P/TBV (Quarterly)4.33x
P/B Ratio (Annual)4.28x
Book Value / Share (Annual)$1.51
Price vs S&P 500 (13W)53.28%
Beta0.02x
P/FCF (Annual)95.23x
Revenue / Share (TTM)$0.00
ROE (TTM)-169.62%
52-Week Low$1.30
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.29
2.29
2.29
2.29
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NERVMinerva Neurosciences, Inc | — | — | — | — | $6.89 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders. Its pipeline includes Roluperidone for schizophrenia negative symptoms, Seltorexant for insomnia and depression, and MIN-301 for Parkinson's disease.